Staff

 

 

 

 


Research Interests

Dr. Jeffrey S. Barrett, is Research Professor of Pediatrics, University of Pennsylvania School of Medicine, the Director of the Laboratory for Applied PK/PD in the Division of Clinical Pharmacology and Therapeutics at the Children's Hospital of Philadelphia (CHOP) and an Associate Scholar in the Center for Clinical Epidemiology and Biostatistics at The University of Pennsylvania. Dr. Barrett served as the Principal Investigator for CHOP's Pediatric Pharmacology Research Unit and heads the Kinetic Modeling and Simulation core of the Penn/CHOP Clinical and Translation Science Award. He also manages the pharmacology and biostatistics cores for several multidisciplinary projects both within CHOP, UPenn and various multi-center cooperative groups. He received his BS from Drexel University in Chemical Engineering and his Ph.D. in Pharmaceutics from the University of Michigan. Dr. Barrett spent 13 years in the pharmaceutical industry involved with PK/PD aspects of clinical drug development and was an early proponent of industrial pharmacometrics prior to joining CHOP. He is a Fellow of the American College of Clinical Pharmacology (ACCP) and the American Association of Pharmaceutical Scientists (AAPS) and received the Young Investigator and Clinical Pharmacology Mentorship Awards from ACCP in 2002 and 2007 respectively. Dr. Barrett was awarded the Research Achievement Award in Clinical Pharmacology and Translational Research from AAPS in 2011. He is a member of the FDA Clinical Pharmacology Advisory Committee, the Board of Directors of the Metrum Research Institute and the Scientific Advisory Board of Pharsight Corporation. Dr. Barrett has co-authored over 100 manuscripts, 135 abstracts and has given over 100 invited lectures on PK/PD, clinical pharmacology and pharmacometrics. He joined the Editorial Boards of the Journal of Clinical Pharmacology in 2007 and the Journal of Pharmacokinetics and Pharmacodynamics in 2009. He has adjunct appointments at the University Of Florida College Of Pharmacy, the University Of Tennessee College Of Pharmacy and Central South University (CSU) and the Third Xiangya Hospital in Changsha, China.

Dr. Barrett has mentored numerous physician fellows and post doctoral candidates in clinical pharmacology and pharmacometrics and continues to evolve his program to accommodate the demand for training in this area. He has hosted visiting professors from Germany (Professor Stephanie Läer), Japan (Professors Hisakasu Ohtani and Toshimi Kimura) and China (Assistant Professor Xiaocong Zuo) over the past few years. Active research agreements exist with Beijing Children's Hospital, the Third Xiangya Hospital and the Istituto Superiore Sanita (ISS). Dr. Barrett was the host for the Sheiner / Rowland Advanced PK/PD Course in 2011 and is creating active training site for workshops and short courses in various topics related to pharmacometrics at CHOP. Many of these are co-sponsored by industry, professional societies and the Metrum Institute which focuses on such training endeavors and in whom Dr. Barrett serves as the Director of Academic Collaborations.

Dr. Barrett's research interest is focused on investigating sources of variation in pharmacokinetics and pharmacodynamics applying clinical pharmacologic investigation coupled with modeling and simulation strategies to pursue rational dosing guidance. He develops pharmacometric approaches to advance PK/PD, medical informatics and disease progression modeling. Dr. Barrett has also integrated model-based decision support systems with hospital electronic medical records and pioneered the pediatric knowledgebase development program for the past 6 years. He is actively involved with creating disease progression models for spinal muscular atrophy (SMA) and pancreatic cancer and his team is developing model-based development approaches for Traditional Chinese Medicine (TCM) and gene therapy.

Recent Presentations:

  1. “Bringing Better Pharmacology Information to Pediatric Caregivers,” NLM Board of Regents Meeting, National Library of Medicine, Bld 28, May 11, 2010
  2. “Enhancing Methotrexate Pharmacotherapy in Children with Cancer: A Decision Support System Integrating Real-time PK/PD Modeling and Simulation with Patient Medical Records,” Annual PAGE Meeting, Berlin, Germany, (PAGE 19 (2010) Abstr 1779 [www.page-meeting.org/?abstract=1779])
  3. “State of the art: Modelling and simulation in paediatric protocol design development, e.g. number of patients and blood samples,” 2nd Expert Workshop: Can the “in silico Child” help to develop better medicines for our children, Badia Benedettina della Castagna, Villa Quartara, Genoa, Italy, September 28-28, 2010.
  4. “Modeling and simulation to define informative experiments,” Systems Biology and Quantitative Pharmacology Workshop, China South University, Changsha, China, December 5-6, 2010.
  5. “The Science of Drug Development: Critical Decisions for Compound Progression,” Institute of Biomedicine, Tsinghua University, Beijing, China, December 11, 2010.
  6. “The Path of Pediatric Drug Development and Informative Trial Design” Beijing Children's Hospital, Beijing, China, December 13, 2010.
  7. “Integration of Modeling and Simulation into Protocol Design Elements,” Pediatric Pharmacology: Utilizing Modeling & Simulation & Population Pharmacokinetic Studies to Optimize Pediatric Drug Development, Philadelphia, PA, January 31-February 1, 2011.
  8. “The Path of Pediatric Drug Development: Necessity of Informative Clinical Trial Design” University of Arizona School of Pharmacy, Phoenix, Arizona, January 25, 2011.
  9. “Statistical Process Control Theory and Effect-Control Hemodynamics to Guide the Management of Sodium Nitroprusside for Controlled Hypotension in Children” American Conference on Pharmacometrics (ACoP), San Diego, California, May, 2011
  10. “Incorporating Metabolism Data into Modeling and Simulation Strategies that Facilitate the Design and Analysis of Pediatric Trials,” 14th Annual Land O Lakes Conference on Drug Metabolism and Applied Pharmacokinetics, University of Wisconsin School of Pharmacy, September 12-16, 2011.

Recent Publications:

  1. Barrett JS, Mondick JT, Narayan M, Vijayakumar K, Vijayakumar S. Integration of Modeling and Simulation into Hospital-based Decision Support Systems Guiding Pediatric Pharmacotherapy. BMC Medical Informatics and Decision Making 8:6, 2008.
  2. Barrett JS. Applying Quantitative Pharmacology in an Academic Translational Research Environment. AAPS Journal 10(1):9-14, 2008.
  3. Barrett JS, Jayaraman B, Patel D, Skolnik JM. A SAS-based solution to evaluate study design efficiency of phase I pediatric oncology trials via discrete event simulation. Computer Methods and Programs in Biomedicine 90: 240-250, 2008.
  4. Thompson PA, Gupta M, Rosner GL, Yu A, Barrett JS, Bomgaars LM, Bernstein ML, Blaney SM, Mondick JT. Pharmacokinetics of Irinotecan and its Metabolites in Pediatric Cancer Patients: A report from the Children's Oncology Group. Cancer Chemotherapy and Pharmacology 62: 1027-37, 2008.
  5. Adamson PC and Barrett JS. All Dex'ed Out With Nowhere To Go? J. Clin Oncol 26(12): 1917-1918, 2008.
  6. Robinson BW, Behling KC, Gupta M, Zhang AY, Moore JS, Bantly AD, Willman CL, Carroll AJ, Adamson PC, Barrett JS, Felix CA: Abundant anti-apoptotic BCL-2 is a molecular target in leukemias with t(4;11) translocation. Br J. Haematol 141(6):827-39, 2008.
  7. Barrett JS, Fossler MJ, Cadieu, KD and Gastonguay MR. Pharmacometrics, A Multidisciplinary Field to Facilitate Critical Thinking in Drug Development and Translational Research Settings. J Clin. Pharmacol 48(5): 632-49, 2008. Published in Chinese Journal as well Chinese J Clin Pharmacol Ther. 13(5): 481-493, 2008.
  8. Zuppa AF, Barrett JS. Pharmacokinetics and pharmacodynamics in the critically ill child. Pediatr Clin North Am. 55(3):735-55, 2008.
  9. Skolnik JM and Barrett JS. Refining the Phase 1 Pediatric Trial. Pediatric Health 2(2): 105-106, 2008.
  10. Gross R, Aplenc R, TenHave T, Foulkes AS, Thakur R, Mosepele M, Barrett JS, Flexner C, Strom BL, Bisson G. Slow Efavirenz Metabolism Genotype is Common in Botswana. J Acquir Immune Defic Syndr 49(3):336-337, 2008.
  11. Barrett JS, Shi J, Xie H, Huang X, Fossler MJ and Sun R. Globalization of Quantitative Pharmacology: First International Symposium of Quantitative Pharmacology in Drug Development and Regulation. J Clin Pharmacol 48(7): 787-792, 2008.
  12. Barrett JS, Patel D, Jayaraman B, Narayan M, Zuppa A. Key Performance Indicators for the Assessment of Pediatric Pharmacotherapeutic Guidance. J Pediatr Pharmacol Ther 13: 141-155, 2008.
  13. Wade KC, Wu D, Kaufman DA, Ward RM, Benjamin DK, Ramey N, Jayaraman B, Kalle H, Adamson PC, Gastonguay M, Barrett JS. Population Pharmacokinetics of Fluconazole in Young Infants. Antimicrob Agents Chemother 52(11):4043-9, 2008.
  14. Barrett JS, Skolnik JM, Jayaraman B, Patel D, Adamson PC. Improving Study Design and Conduct Efficiency of Event-Driven Clinical Trials via Discrete Event Simulation: Application to Pediatric Oncology. Clinical Pharmacol Ther 84(6): 729-733, 2008.
  15. Menon-Andersen D, Mondick JT, Jayaraman B, Thompson PA, Blaney SM, Adamson PC, Barrett JS. Population Pharmacokinetics of Imatinb Mesylate and its Metabolite in Children and Young Adults. Cancer Chemother and Pharmacol 63(2):229-38, 2009.
  16. Rowan C, Brinker AD, Nourjah, P, Chang J, Mosholder A, Barrett JS, Avigan M. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf 18(4):301-309, 2009.
  17. Wade KC, Benjamin Jr. DK, Kaufman DA, Ward RM, Smith PB, Jayaraman B, Adamson PC, Gastonguay M, Barrett JS. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Ped Infectious Disease J 28(8): 717-23, 2009.
  18. Läer S, Barrett JS, and Meibohm B. The In Silico Child: Using Simulation to Guide Pediatric Drug Development and Manage Pediatric Pharmacotherapy. J Clin Pharmacol 49(8): 889-904, 2009.
  19. Wu D, Wade KC, Paul DJ, Barrett JS. A rapid, sensitive LC-MS/MS method for determination of fluconazole in human plasma and its application in infants with Candida infections, J Therapeutic Drug Monitoring 31(6): 703-9, 2009.
  20. Mondick JT, Johnson BM, Haberer LJ, Sale ME, Adamson PC, Barrett JS, Coté CJ, Croop JM, Russo MW, Hoke JF. Population Pharmacokinetics of Intravenous Ondansetron in oncology and surgical patients aged 1 to 48 months. Eur. J. Clin Pharmacol 66(1): 77-86, 2010.
  21. Shi J and Barrett, JS. Pharmacometrics in pediatric drug development and rationale dosage. Chinese J Clin Pharm Ther 15(1): 1-10, 2010.
  22. Su F, Nicolson SC, Gastonguay MR, Barrett JS, Adamson PC, Kang DS, Godinez RI, Zuppa AF. Population Pharmacokinetics of Dexmedetomidine in Infants Following Open Heart Surgery. Anesth Analg. 110(5):1383-92, 2010.
  23. Marsenic O, Zhang L, Zuppa A, Barrett JS, Pfister M. Application of Individualized Bayesian Urea Kinetic Modeling to pediatric hemodialysis. ASAOI J 56(3):246-53, 2010.
  24. Kimura T, Kashiwase S, Makimoto A, Kumagai M, Taga T, Ishida Y, Ida K, Nagatoshi Y, Mugishima H, Kaneko M, Barrett JS. Pharmacokinetic and pharmacodynaminc Investigation of Irinotecan hydrochloride in Pediatric Patients with Recurrent or Progressive Solid Tumors. Int J Clin Pharmacol Ther. 48(5):327-334, 2010.
  25. Skolnik JM, Zhang AY, Barrett JS, and Adamson PC. Approaches to clear residual chemotherapeutics from indwelling catheters in children with cancer J. Ther. Drug Monitoring 32(6): 741-8, 2010.
  26. Langholz B, Skolnik J, Barrett JS, Renbarger J, Seibel N, Zajicek A, Arndt C. Dactinomycin and vincristine toxicity in the treatment of childhood cancer: A retrospective study from the Children's Oncology Group. Pediatric Blood & Cancer 57(2):252-7, 2011.
  27. Dombrowsky E, Jayaraman B, Narayan M, Barrett JS. Evaluating Performance of a Decision Support System to Improve Methotrexate Pharmacotherapy in Children with Cancer. J. Ther. Drug Monitoring 33(1): 99-107, 2011.
  28. Piper L, Smith B, Hornik CP, Cheifetz IM, Barrett JS, Moorthy G, Wade KC, Cohen-Wolkowiesz, Benjamin DK. Fluconazole Loading Dose Pharmacokinetics and Safety in Infants. Pediatric Infectious Disease J 30(5): 375-8, 2011.
  29. Barrett JS, Zuppa AF, Adamson PC, Patel D and Narayan M. Prescribing Habits and Caregiver Satisfaction with Resources for Dosing Children: Rationale for More Informative Dosing Guidance. BMC Pediatrics 11: 25, 2011.
  30. Zuppa AF, Nicolson SC, Barrett JS, Kang DS, Gastonguay MR. Population Pharmacokinetics of Pentobarbital in Neonates, Infants and Children Following Open Heart Surgery. J. Pediatrics 159(3):414-419, 2011.
  31. Maitland ML, Bies RR, Barrett JS. A Time to Keep and a Time to Cast Away Categories of Tumor Response. J Clin Oncology 29(23):3109-11, 2011.
  32. Tebas P, Tuluc F, Barrett JS, Wagner W, Kim D, Zhao H, Gonin R, Korelitz J, Douglas SD. A Phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. PLoS One. 6(9):e24180, 2011.

 

 

 

 

Jeffery S. Barrett Ph.D, FCP
Director, Laboratory for Applied PK/PD
Research Professor, Department of Pediatrics
Core Director, KMAS
Email: barrettj@email.chop.edu
Phone: 267-426-5479